Medication Monitor

Generic Name (Trade Name—Company)
October 30, 2019

Trifarotene cream

(Aklief Cream, 0.005%—Galderma)
New topical retinoid treats acne in patients ages 9 and older

On October 7, Galderma announced FDA approval of trifarotene cream, 0.005%, for topical treatment of acne in patients ages 9 years and older. It is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin, and is the first new retinoid to receive FDA approval for treatment of acne in more than 20 years. It will be provided in a 45-g pump. 

The most common adverse reactions are application site irritation, application site pruritus, and sunburn.

The medication is expected to be available in the United States in November 2019. Galderma is working closely with payers, providers, and pharmacy benefit managers to ensure broad and rapid access. The company will also offer a patient savings card program, Galderma CareConnect.